Stacey Chuma

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

Steven P. Treon, Christina Tripsas, Kirsten Meid et al. · Blood · 2014 · 177 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +4

Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia

Irene M. Ghobrial, Fangxin Hong, Ashraf Badros et al. · Journal of Clinical Oncology · 2010 · 165 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

Irene M. Ghobrial, Wanling Xie, Ashraf Badros et al. · American Journal of Hematology · 2010 · 148 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia

Irene M. Ghobrial, Morie A. Gertz, Betsy LaPlant et al. · Journal of Clinical Oncology · 2010 · 134 citations · Full text

Medicine, Oncology, Pharmacology +13

Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia

Irene M. Ghobrial, Aldo M. Roccaro, Fangxin Hong et al. · Clinical Cancer Research · 2010 · 107 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12